Active Ingredient History
Tamibarotene, also called retinobenzoic acid, is orally active, synthetic retinoid, developed to overcome all-trans retinoic acid (ATRA) resistance, with potential antineoplastic activity against acute promyelocytic leukaemia (APL). It is currently marketed only in Japan and early trials have demonstrated that it tends to be better tolerated than ATRA. It has also been investigated as a possible treatment for Alzheimer's disease, multiple myeloma and Crohn's disease. Tamibarotene is found to have inhibitory potential for the viral spike protein of Omicron variant of SARS-CoV2 and can be a potential candidate for developing potential therapeutics for the treatment of omicron variant of COVID19. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Alzheimer Disease (Phase 2)
Carcinoma, Hepatocellular (Phase 1/Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Crohn Disease (Phase 2)
Leukemia, Myeloid, Acute (Phase 2)
Leukemia, Promyelocytic, Acute (Phase 2)
Lupus Nephritis (Phase 2)
Myelodysplastic Syndromes (Phase 2)
Pancreatic Neoplasms (Phase 1/Phase 2)
Paraparesis, Tropical Spastic (Phase 2/Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue